Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 500 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus ( Type 1 and Type 2) Clear all
Recruiting Phase 1 Interventional

A Phase 1, Multiple Ascending Dose Study to Evaluate HMS1005 in Participants With Type 2 Diabetes

NCT07568678
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
HMS1005, Matching placebo
Drug
Lead sponsor
Hua Medicine Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 31, 2026, 1:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects

NCT02106585
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
JTT-251 or Placebo
Drug
Lead sponsor
Shionogi Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Oct 31, 2026, 1:21 PM EDT
Completed Not applicable Interventional Results available

Evaluation of the Accuracy of an Implanted Glucose Sensor

NCT02647905
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Continuous Glucose Monitoring System
Device
Lead sponsor
Senseonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
9
States / cities
Concord, California • Escondido, California • Walnut Creek, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 31, 2026, 1:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)

NCT00915954
View directory record Official record
Conditions
Acromegaly, Type 2 Diabetes Mellitus
Interventions
Oral Glucose Tolerance Test, Subcutaneous administration of recombinant human IGF-1, Placebo
Diagnostic Test
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 31, 2026, 1:21 PM EDT
Completed Phase 2 Interventional

Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

NCT01452451
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
HM11260C, Placebo
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Ohio City, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Oct 31, 2026, 1:21 PM EDT
Completed No phase listed Observational

Description of Patients With Type 1 Diabetes Treated With Teplizumab

NCT06892002
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Teplizumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
Not listed
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
24
States / cities
Little Rock, Arkansas • San Francisco, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 31, 2026, 1:21 PM EDT
Completed Not applicable Interventional Results available

Two Way Crossover Closed Loop MPC vs Control IQ

NCT05799781
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
MPC closed-loop system, t:slim X2 pump with Dexcom G6 CGM and Control IQ
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 31, 2026, 1:21 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.

NCT01843127
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Ranolazine, Placebo, Exenatide
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
3
States / cities
Chula Vista, California • Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Oct 31, 2026, 1:21 PM EDT
Terminated Phase 3 Interventional

Efficacy an Safety of Volinanserin on Sleep Maintenance Insomnia With a Sub-study on Stable Type II Diabetes Mellitus

NCT00464061
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders
Interventions
Volinanserin, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,847 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 31, 2026, 1:21 PM EDT
Completed No phase listed Observational

Adipose Tissue Function After Pancreas Transplantation

NCT01729130
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, End Stage Renal Disease
Interventions
Adipose tissue biopsy
Procedure
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 31, 2026, 1:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460A

NCT01724814
View directory record Official record
Conditions
Healthy, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
HM12460A, Placebo
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 31, 2026, 1:21 PM EDT
Not yet recruiting Not applicable Interventional

Care COMPASS Study

NCT07904793
View directory record Official record
Conditions
Diabetes Mellitus ( Type 1 and Type 2), Hypertension
Interventions
Guide My Care Tool
Other
Lead sponsor
Fitbit LLC
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 31, 2026, 1:21 PM EDT
Completed Phase 1 Interventional Results available

Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

NCT01673178
View directory record Official record
Conditions
Diabetes Melliuts, Type 2
Interventions
Placebo, 25 mg PF-05231023, 50 mg PF-05231023, 100 mg PF-05231023, 150 mg PF-05231023
Other · Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
17
States / cities
Anaheim, California • Chula Vista, California • Walnut Creek, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 31, 2026, 1:21 PM EDT
Completed Phase 1 Interventional Results available

Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes

NCT01285518
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PF-05231023, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
5
States / cities
Chula Vista, California • Fort Meyers, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2016 · Synced Oct 31, 2026, 1:21 PM EDT
Terminated Phase 3 Interventional

Inhaled Technosphere Insulin in Subjects With Diabetes Mellitus and Asthma

NCT00332826
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Asthma
Interventions
Technosphere Insulin
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
25
States / cities
Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated May 4, 2012 · Synced Oct 31, 2026, 1:21 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Analysis of the NuStep as an Introductory Fitness Regimen

NCT00954694
View directory record Official record
Conditions
Diabetes, Inactivity
Interventions
NuStep fitness apparatus
Device
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 7, 2009 · Synced Oct 31, 2026, 1:21 PM EDT
Completed Not applicable Interventional

A Continuous Glucose Monitor Based Insulin Bolus Calculator

NCT05229445
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions
continuous glucose monitor based insulin bolus calculator
Device
Lead sponsor
Welldoc
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Oct 31, 2026, 1:21 PM EDT
Completed Not applicable Interventional Results available

Evaluation of Accuracy of Continuous Glucose Monitoring (CGM) in Patients With End Stage Renal Disease (ESRD) on Intermittent Hemodialysis (iHD).

NCT04094064
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Continuous Glucose Monitor
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 31, 2026, 1:21 PM EDT
Completed Phase 3 Interventional Results available

G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes

NCT03439072
View directory record Official record
Conditions
Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia
Interventions
G-Pen, Lilly Glucagon
Drug
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
4
States / cities
Chula Vista, California • Walnut Creek, California • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 31, 2026, 1:21 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function

NCT04628481
View directory record Official record
Conditions
Recent Onset type1 Diabetes
Interventions
Ladarixin, Placebo
Drug
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
14 Years to 45 Years
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 31, 2026, 1:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug to Drug Interaction Study of Sotagliflozin With Hydrochlorothiazide

NCT03387657
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin (SAR439954), Hydrochlorothiazide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 31, 2026, 1:21 PM EDT
Completed Phase 1 Interventional Results available

A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus

NCT02211261
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
PF-06293620, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
7
States / cities
Chula Vista, California • DeLand, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 31, 2026, 1:21 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C

NCT02383940
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 30 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
Tustin, California • Aurora, Colorado • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Oct 31, 2026, 1:21 PM EDT
Completed Not applicable Interventional

Blood Glucose Awareness Training for Parents

NCT00315991
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Blood Glucose Awareness Training for Parents
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
6 Years to 11 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Boston, Massachusetts • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 31, 2026, 1:21 PM EDT